Maximus (NYSE:MMS) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Maximus (NYSE:MMS) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Other research analysts also recently issued research reports about the company. Weiss Ratings downgraded Maximus from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 20th. Zacks Research cut Maximus from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Maximus Price Performance

MMS opened at $59.21 on Friday. The stock has a 50-day moving average price of $58.63 and a 200-day moving average price of $67.46. Maximus has a 12-month low of $52.73 and a 12-month high of $100.00. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 0.90. The stock has a market capitalization of $3.11 billion, a P/E ratio of 8.75 and a beta of 0.59.

Maximus (NYSE:MMS) last announced its quarterly earnings data on Thursday, August 6th. The health services provider reported $2.22 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.01. The company had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.33 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%.Maximus’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period last year, the firm posted $2.16 EPS. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. Equities analysts predict that Maximus will post 8.05 earnings per share for the current fiscal year.

Maximus Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be paid a $0.33 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.32 annualized dividend and a dividend yield of 2.2%. Maximus’s dividend payout ratio (DPR) is presently 19.76%.

Hedge Funds Weigh In On Maximus

A number of hedge funds and other institutional investors have recently made changes to their positions in MMS. Seizert Capital Partners LLC bought a new position in shares of Maximus in the 4th quarter worth approximately $1,863,000. Ruffer LLP bought a new position in Maximus in the fourth quarter worth $6,951,000. UBS Group AG raised its holdings in Maximus by 76.8% in the fourth quarter. UBS Group AG now owns 610,354 shares of the health services provider’s stock worth $52,686,000 after purchasing an additional 265,095 shares in the last quarter. Reinhart Partners LLC. lifted its position in Maximus by 131.8% during the second quarter. Reinhart Partners LLC. now owns 1,982,415 shares of the health services provider’s stock valued at $106,575,000 after buying an additional 1,127,346 shares during the period. Finally, Comerica Bank lifted its position in Maximus by 124.4% during the fourth quarter. Comerica Bank now owns 61,284 shares of the health services provider’s stock valued at $5,290,000 after buying an additional 33,973 shares during the period. Institutional investors own 97.21% of the company’s stock.

Maximus News Summary

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Fiscal Q3 adjusted earnings were $2.22 per share, ahead of analyst estimates of approximately $2.20–$2.21 and up from $2.16 a year earlier. Higher margins also supported the quarter’s bottom-line performance. Maximus Q3 Earnings Beat Estimates, Increase Year Over Year
• Positive Sentiment: The earnings beat, year-over-year EPS growth and stronger margins indicate that Maximus is maintaining profitability even as sales soften. Maximus Q3 Earnings Beat Estimates
• Neutral Sentiment: Management’s fiscal Q3 earnings call focused on the quarterly performance and updated outlook, providing investors with additional context on operating trends and the company’s expectations for the remainder of fiscal 2026. Maximus Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue was $1.28 billion, below the $1.33 billion consensus estimate and down 5.1% year over year. The shortfall suggests softer demand or project timing is limiting growth. Maximus Fiscal Q3 Earnings Snapshot
• Negative Sentiment: Maximus reduced fiscal 2026 EPS guidance to $7.90–$8.20, below the consensus estimate of $8.43. Revenue guidance of $5.2–$5.4 billion remains broadly in line with expectations at the midpoint, but the lower profit outlook is a key overhang for MMS. Updated Maximus Fiscal 2026 Guidance

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.